Repligen | RGEN - Ordinary Share Capital


Repligen reported $56.4M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Agilent USD 282.22M 478K Mar/2026
Align Technology USD 71.62M 133K Mar/2026
Bio Techne USD 156.45M 703K Mar/2026
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Bruker USD 152.22M 282K Mar/2026
Charles River Laboratories USD 48.17M 1.05M Mar/2026
Danaher USD 707.7M 800K Mar/2026
Dentsply International USD 200.3M 700K Mar/2026
General Electric Aerospace USD 1.04B 5.43M Mar/2026
Henry Schein USD 114.42M 1.35M Mar/2026
Illumina USD 151.91M 893K Mar/2026
IQVIA Holdings USD 166.9M 2.7M Mar/2026
Mettler Toledo International USD 20.25M 179.94K Mar/2026
Myriad Genetics USD 93.5M 400K Dec/2025
OraSure Technologies USD 70.39M 1.87M Dec/2025
Pacific Biosciences Of California USD 301.96M 103K Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Repligen USD 56.4M 74K Mar/2026
Revvity USD 111.8M 1.57M Mar/2026
Standard Biotools USD 386.38M 2.77M Dec/2025
Thermo Fisher Scientific USD 371.62M 4.09M Mar/2026
Waters USD 98.17M 89K Mar/2026
West Pharmaceutical Services USD 70.9M 1.1M Mar/2026